Switch to the current Annual Report
As a startup founder, I learned how critical messaging is to business success. I am so thankful for SBDC's help in crafting our compelling pitch so we properly convey our value to raise funding, sell our product, and create partnerships.
Tim Near, Founder & CEO, Cyborg
As a startup founder, I learned how critical messaging is to business success. I am so thankful for SBDC's help in crafting our compelling pitch so we properly convey our value to raise funding, sell our product, and create partnerships.
Tim Near, Founder & CEO, Cyborg
As a startup founder, I learned how critical messaging is to business success. I am so thankful for SBDC's help in crafting our compelling pitch so we properly convey our value to raise funding, sell our product, and create partnerships.
Tim Near, Founder & CEO, Cyborg
As a startup founder, I learned how critical messaging is to business success. I am so thankful for SBDC's help in crafting our compelling pitch so we properly convey our value to raise funding, sell our product, and create partnerships.
Tim Near, Founder & CEO, Cyborg
As a startup founder, I learned how critical messaging is to business success. I am so thankful for SBDC's help in crafting our compelling pitch so we properly convey our value to raise funding, sell our product, and create partnerships.
Tim Near, Founder & CEO, Cyborg
$2.15M
Capital Formation from Technology Commercialization in 2020
$2.15M
Capital Formation from Technology Commercialization in 2020
$2.15M
Capital Formation from Technology Commercialization in 2020
$2.15M
Capital Formation from Technology Commercialization in 2020
$2.15M
Capital Formation from Technology Commercialization in 2020
Brian Duboff has been a godsend ever since. This has really resonated. He's been a big help to find market research information, reports for us to use and to bolster the case for the size of the market and where we should put our resources.
Simon Woodruff, CEO, Sci Vista, LLC
Brian Duboff has been a godsend ever since. This has really resonated. He's been a big help to find market research information, reports for us to use and to bolster the case for the size of the market and where we should put our resources.
Simon Woodruff, CEO, Sci Vista, LLC
Brian Duboff has been a godsend ever since. This has really resonated. He's been a big help to find market research information, reports for us to use and to bolster the case for the size of the market and where we should put our resources.
Simon Woodruff, CEO, Sci Vista, LLC
Brian Duboff has been a godsend ever since. This has really resonated. He's been a big help to find market research information, reports for us to use and to bolster the case for the size of the market and where we should put our resources.
Simon Woodruff, CEO, Sci Vista, LLC
Brian Duboff has been a godsend ever since. This has really resonated. He's been a big help to find market research information, reports for us to use and to bolster the case for the size of the market and where we should put our resources.
Simon Woodruff, CEO, Sci Vista, LLC
Quadrant Biosciences, Founder, Richard Uhlig
Quadrant Biosciences was founded by Richard Uhlig after his son got a concussion playing hockey. As his company grew, he partnered with SUNY Upstate Medical University to develop epigenetic tests for concussion, autism & Parkinson's disease. The Binghamton SBDC helped him with marketing diagnostic tests, filing grant applications and lender introductions. The company has received $5 million in grant awards & $33 million in private funding. Recently FDA approved his saliva test for Covid.
Quadrant Biosciences, Founder, Richard Uhlig
Quadrant Biosciences was founded by Richard Uhlig after his son got a concussion playing hockey. As his company grew, he partnered with SUNY Upstate Medical University to develop epigenetic tests for concussion, autism & Parkinson's disease. The Binghamton SBDC helped him with marketing diagnostic tests, filing grant applications and lender introductions. The company has received $5 million in grant awards & $33 million in private funding. Recently FDA approved his saliva test for Covid.
Quadrant Biosciences, Founder, Richard Uhlig
Quadrant Biosciences was founded by Richard Uhlig after his son got a concussion playing hockey. As his company grew, he partnered with SUNY Upstate Medical University to develop epigenetic tests for concussion, autism & Parkinson's disease. The Binghamton SBDC helped him with marketing diagnostic tests, filing grant applications and lender introductions. The company has received $5 million in grant awards & $33 million in private funding. Recently FDA approved his saliva test for Covid.
Quadrant Biosciences, Founder, Richard Uhlig
Quadrant Biosciences was founded by Richard Uhlig after his son got a concussion playing hockey. As his company grew, he partnered with SUNY Upstate Medical University to develop epigenetic tests for concussion, autism & Parkinson's disease. The Binghamton SBDC helped him with marketing diagnostic tests, filing grant applications and lender introductions. The company has received $5 million in grant awards & $33 million in private funding. Recently FDA approved his saliva test for Covid.
Quadrant Biosciences, Founder, Richard Uhlig
Quadrant Biosciences was founded by Richard Uhlig after his son got a concussion playing hockey. As his company grew, he partnered with SUNY Upstate Medical University to develop epigenetic tests for concussion, autism & Parkinson's disease. The Binghamton SBDC helped him with marketing diagnostic tests, filing grant applications and lender introductions. The company has received $5 million in grant awards & $33 million in private funding. Recently FDA approved his saliva test for Covid.
Xona Microfluidics Relies on STTR Funds to Finance Future
Xona Microfluidics began working with the SBTDC in 2011 to get help with securing financing from the NIH's Small Business Technology Transfer (STTR) program. Since 2013, Xona has received nearly $3 million in STTR grants, including a $678K Phase I grant, a $1.9M Phase II grant, and a $225K Phase I grant. The STTR funding has allowed Xona to finance commercialization of its product, including identifying potential customers, marketing, and investment in R&D to make the product more user-friendly.
Xona Microfluidics Relies on STTR Funds to Finance Future
Xona Microfluidics began working with the SBTDC in 2011 to get help with securing financing from the NIH's Small Business Technology Transfer (STTR) program. Since 2013, Xona has received nearly $3 million in STTR grants, including a $678K Phase I grant, a $1.9M Phase II grant, and a $225K Phase I grant. The STTR funding has allowed Xona to finance commercialization of its product, including identifying potential customers, marketing, and investment in R&D to make the product more user-friendly.
Xona Microfluidics Relies on STTR Funds to Finance Future
Xona Microfluidics began working with the SBTDC in 2011 to get help with securing financing from the NIH's Small Business Technology Transfer (STTR) program. Since 2013, Xona has received nearly $3 million in STTR grants, including a $678K Phase I grant, a $1.9M Phase II grant, and a $225K Phase I grant. The STTR funding has allowed Xona to finance commercialization of its product, including identifying potential customers, marketing, and investment in R&D to make the product more user-friendly.
Xona Microfluidics Relies on STTR Funds to Finance Future
Xona Microfluidics began working with the SBTDC in 2011 to get help with securing financing from the NIH's Small Business Technology Transfer (STTR) program. Since 2013, Xona has received nearly $3 million in STTR grants, including a $678K Phase I grant, a $1.9M Phase II grant, and a $225K Phase I grant. The STTR funding has allowed Xona to finance commercialization of its product, including identifying potential customers, marketing, and investment in R&D to make the product more user-friendly.
Xona Microfluidics Relies on STTR Funds to Finance Future
Xona Microfluidics began working with the SBTDC in 2011 to get help with securing financing from the NIH's Small Business Technology Transfer (STTR) program. Since 2013, Xona has received nearly $3 million in STTR grants, including a $678K Phase I grant, a $1.9M Phase II grant, and a $225K Phase I grant. The STTR funding has allowed Xona to finance commercialization of its product, including identifying potential customers, marketing, and investment in R&D to make the product more user-friendly.